Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trial
⟶ Eli Lilly's experimental drug retatrutide has demonstrated superior results to Ozempic in a clinical trial, showing greater weight loss and improved blood sugar control. The drug achieved more than double the weight loss seen with Ozempic's highest approved dose and a greater reduction in A1C levels.
New weight loss drug retatrutide provides double the weight loss of Ozempic, Lilly says; Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial.
Background
Retatrutide is a new obesity drug candidate developed by Eli Lilly. Ozempic, manufactured by Novo Nordisk, is a widely recognized medication for type 2 diabetes that has also gained popularity for its weight loss effects. This trial aimed to directly compare the efficacy of retatrutide against Ozempic in a head-to-head study.
Why it matters
The trial results suggest that retatrutide could be a more effective treatment option for both weight management and diabetes control compared to existing popular medications. This potential advancement is significant in the ongoing development of therapies for metabolic diseases.
Possible impact
The promising results could lead to increased competition in the lucrative obesity and diabetes drug markets. Investors and patients will be closely watching regulatory approvals and future market performance of retatrutide.